COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Cargo, fishing vessels collide in Bohai Sea, search for missing underway
- China's first 8K space film ?SHENZHOU 13 premieres in Shanghai
- Flags spotlight Hebei's enduring war legacy
- Harbin Institute of Technology opens China-SCO doctoral training center
- Xi extends congratulations to plenary session of China-Russia friendship committee
- China unveils asteroid defense mission plan
